Monday, December 11, 2023
11:23 AM EST – Eupraxia Pharmaceuticals Inc. : Announced updates for its two clinical programs, EP-104IAR, its lead drug candidate in development for the treatment of knee osteoarthritis, and EP-104GI, a high-potential product candidate in development for the treatment of eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc. (T.EPRX ) shares were down $0.32 at 5.54.
Stocks in Play: Eupraxia Pharmaceuticals Inc., Mon, 11 Dec 2023 11:27:06 EST